Neurogenic detrusor overactivity in adults: A review on efficacy, tolerability and safety of oral antimuscarinics

Spinal Cord

Volumn 51, Issue 6, 2013, Pages 432-441

  Madersbacher, H ^a   Murtz G ^b   Stohrer M ^c  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b University of Essen ^*

^c UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

antimuscarinic drugs; efficacy; humans; neurogenic bladder; neurogenic detrusor overactivity; tolerability and safety of antimuscarinics

Indexed keywords

FESOTERODINE; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; PLACEBO; PROPIVERINE; SOLIFENACIN; TOLTERODINE; TROSPIUM CHLORIDE;

ADULT DISEASE; BLADDER PRESSURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; INCIDENCE; NEUROGENIC BLADDER; OVERACTIVE BLADDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT; URINE INCONTINENCE; XEROSTOMIA;

ADMINISTRATION, ORAL; ADULT; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; MALE; MUSCARINIC ANTAGONISTS; URINARY BLADDER, OVERACTIVE;

EID: 84878915481     PISSN: 13624393     EISSN: 14765624     Source Type: Journal    
DOI: 10.1038/sc.2013.19     Document Type: Review

References (42)

1. Chapple C, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. The effects of antimuscarinic tretaments in overactive bladder: An update of a systematic review and meta-analysis. Eur Urol 2008; 54, 543-562.
2. Novara G, Galfano A, Ficarra V, Artibani W. Anticholinergic drugs in patients with bladder outlet obstruction and lower urinary tract symptoms: a systematic review. Eur Urol 2006; 50, 675-683. (Pubitemid 44332687)
3. Kaplan SA, Roehrborn CG, Abrams P, Chapple CR, Bavendam T, Guan Z. Antimuscarinics for treatment of storage lower urinary tract symptoms in men: a systematic review. Int J Clin Pract 2011; 65, 487-507.
4. Stohrer M, Blok B, Castro-Diaz D, Chartier-Kastler E, Del Popolo G, Kramer G et al. EAU guidelines on neurogenic lower urinary tract dysfunction. Eur Urol 2009; 56, 81-88.
5. Madhuvrata P, Hasafa Z, Singh M, Abdel-Fattah M. Anticholinergic drugs for adult neurogenic detrusor overactivity: a systematic review and meta-analysis. Eur Urol 2012; 62, 816-830.
6. Bycroft J, Leaker B, Wood S, Knight S, Shah G, Craggs M. The effect of darifenacin on neurogenic detrusor overactivity in patients with spinal cord injury. Annual meeting of the International Continence Society, Florence, Italy, 2003 Neurourol Urodyn 2003; 22, A190.
7. Kennelly MJ, Lemack GE, Foote JE, Trop CS. Efficacy and safety of oxybutynin transdermal system in spinal cord injury patients with neurogenic detrusor overactivity and incontinence: an open-label, dose-titration study. Urology 2009; 74, 741-745.
8. Pannek J, Sommerfeld HJ, Botel U, Senge T. Combined intravesical and oral oxybutynin chloride in adult patients with spinal cord injury. Urology 2000; 55, 358-362. (Pubitemid 30110584)
9. Oxford Centre for Evidence-based Medicine Levels of evidence (May 2011). Produced by Bob Philips, Dave Sackett, Doug Badenoch, Sharon Straus, Brian Haynes, Martin Dawessince November. 1998.
10. Mazur D, Gocking K, Wehnert J, Schubert G, Herfurth G, Alken RG. Clinical and urodynamic effects of oral propiverine therapy in neurogenic urinary incontinence: a multicentre dose-optimizing study. Urologe A 1994; 33, 447-452. (Pubitemid 24282969)
11. Van Kerrebroeck P, Amarenco G, Thu roff J, Madersbacher HG, Lock MT, Messelink EJ et al. Dose-ranging study of tolterodine in patients with detrusor hyperreflexia. Neurourol Urodyn 1998; 17, 499-512. (Pubitemid 28462643)
12. Stohrer M, Bersch U, Gocking K, Schurch B, Kramer G. Dose finding study for treatment of detrusor hyperreflexia by trospium chloride. Presented at: Annual Meeting of the International Medical Society of Paraplegia. Iguassu, Brazil 1998.
13. Stohrer M, Frohneberg D, Loechner-Ernst D, Sauter P, Mandaika B. Oxybutynin in the treatment of detrusor hyperreflexia in patients with spinal cord injury: A multicentre randomised double-blind study. Presented at: Annual Meeting of the American Spinal Cord Injury Association. Orlando, USA 1990.
14. Stohrer M, Madersbacher H, Richter R, Wehnert J, Dreikorn K. Efficacy and safety of propiverine in SCI-patients suffering from detrusor hyperreflexia-a double-blind, placebo-controlled clinical trial. Spinal Cord 1999; 37, 196-200. (Pubitemid 29149996)
15. Stohrer M, Bauer P, Giannetti BM et al. Effect of trospium chloride on urodynamic parameters in patients with detrusor hyperreflexia due to spinal cord injuries. A multicentre placebo-controlled double-blind trial. Urol Int 1991; 47, 138-143.
16. Ethans KD, Nance PW, Bard RJ, Casey AR, Schryvers OI. Efficacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med 2004; 27, 214-218. (Pubitemid 44210644)
17. Amarenco G, Sutory M, Fagertun H, Wright M, Compion G, DeRidder D. Solifenacin is effective and well tolerated in patients with neurogenic detrusor overactivity. Preliminary results from the SONIC urodynamic study. Eur Urol Suppl 2012; 11, e467.
18. Gajewski JB, Awad SA. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperreflexia. J Urol 1986; 135, 966-968. (Pubitemid 16077221)
19. Madersbacher H, Stohrer M, Richter R, Burgdo rfer H, Hachen HJ, Mu rtz G. Trospium chloride versus oxybuynin: a randomized, double-blind, multicentre trial in the treatment of detrusor hyperreflexia. Brit J Urol 1995; 75, 452-456.
20. Stohrer M, Mu rtz G, Kramer G, Schnabel F, Arnold EP, Wyndaele JJ. Propiverine Study Group. Propiverine compared to oxybutynin in neurogenic detrusor overactivity-results of a randomized, double blind, multicenter clinical study. Eur Urol 2007; 51, 235-242. (Pubitemid 44821506)
21. Stohrer M, Mu rtz G, Kramer G, Warnack W, Primus G, Jinga V et al. Efficacy and tolerability of propiverine hydrochloride extended release compared to immediate release in patients with neurogenic detrusor overactivity. Spinal Cord 2013; 51, 209-213.
22. Bennett N, O'Leary M, Patel AS, Xavier M, Erickson JR, Chancellor MB. Can higher doses of oxybutynin improve efficacy in neurogenic bladder? J Urol 2004; 171, 749-751. (Pubitemid 38090473)
23. O'Leary M, Erickson JR, Smith CP, McDermott C, Horton J, Chancellor MB. Effect of controlled-release oxybutynin on neurogenic bladder function in spinal cord injury. J Spinal Cord Med 2003; 26, 159-162. (Pubitemid 36834721)
24. Menarini M, Del Popolo G, Benedetto D, Haselmann J, Bodeker RH, Schwantes U et al. Trospium chloride in patients with neurogenic detrusor overactivity: Is dose titration of benefit to the patients? Int J Clin Pharmacol Ther 2006; 44, 623-632. (Pubitemid 44896140)
25. Persu C, Gaevlete PA. Double dose of solifenacin for the treatment of neurogenic detrusor overactivity. Eur Urol Suppl 2012; 11, e469.
26. Horstmann M, Schaefer T, Aguilar Y, Stenzl A, Sievert KD. Neurogenic bladder treatment by doubling the recommended antimuscarinic dosage. Neurourol Urodyn 2006; 25, 441-445.
27. Amend B, Hennenlotter J, Schaefer T, Horstmann M, Stenzl A, Sievert KD. Effective treatment of neurogenic detrusor dysfunction by combined high-dosed antimuscarinics without increased side-effects. Eur Urol 2008; 53, 1021-1028.
28. Cameron AP, Clemens JQ, Latini JM, McGuire EJ. Combination drug therapy improves compliance of the neurogenic bladder. J Urol 2009; 182, 1062-1067.
29. Madersbacher M, Stohrer M, Richter R, Giannetti BM, Mu rtz G. High-dose administration of trospium chloride in the treatment of detrusor hyperreflexia. Urologe 1991; 30, 260-263.
30. Geirsson G, Schoefield D, Haughie S, Steihdotsdottir S, Hardardottir A, Glue P et al. Assessment of time to onset: the effect of single oral dose of tolterodine on neurogenic detrusor overactivity in spinal cord injury patients. Presented at: Annual Meeting of the International Continence Society 2006, (Abstract 309).
31. Yamanishi T, Mizuro T, Yoshida K, Uchiyama T, Sakakibara R. Efficacy of tolterodine ER for the treatment of neurogenic detrusor overactivity or low compliance bladder-assessment by urodynamic study. Presented at: Annual Meeting of the International Continence Society 2009, (Abstract 330).
32. Carl S, Laschke S. Darifenacin is also effective in neurogenic bladder dysfunction (multiple sclerosis). Urology 2006; 68 (Suppl), 250.
33. Spinelli M, Citari M, Zanollo L et al. Solifenacin in neurogenic overactive bladder. Eur Urol Suppl 2007; 6, 273.
34. van Rey F, Heesakkers J. Solifenacin in multiple sclerosis patients with overactive bladder: a prospective study. Adv Urol 2011; 2011, 834753.
35. Mazur D, Gocking K, Wehnert J, Dorschner W, Schubert G, HerFurth G et al. Vertraglichkeit und Wirksamkeit einer Langzeittherapie mit Propiverinhydrochlorid bei neurogener Hatrninkontinenz. Eine multizentrische Studie. Kontinenz 1994; 2, 74-78.
36. Proietti S, Lepri E, Lepri L, Lolli C, Gubbiotti M, Giannantoni A. Efficacy and tolerability of fesoterodine fumarate in the treatment of overactive bladder symptoms in patients affected by multiple sclerosis: Long term follow up. Eur Urol Suppl 2012; 11, e468.
37. Tan YK, Toh KL. Tolterodine improves the compliance and cystometric capacity of adult neurogenic bladders secondary to spinal cord injury. Presented at: Annual Meeting of the International Continence Society 2009, (Abstract 331).
38. Digesu GA, Khullar V, Cardozo L, Salvatore S. Overactive bladder symptoms: do we need urodynamics? Neurourol Urodyn 2003; 22, 105-108. (Pubitemid 36222869)
39. McGuire EJ, Woodside JR, Borden TA, Weiss RM. Prognostic value of urodynamic testing in myelodysplastic patients. J Urol 1981; 126, 205-209. (Pubitemid 11012925)
40. Kessler TM, Bachmann LM, Minder C, Lohrer D, Umbehr M, Schunemann HJ et al. Adverse event assessment of antimuscarinics for treating overactive bladder: A network meta-analytic apoproach. PLoS One 2011; 6, e16718.
41. Uchiyama T, Sakakibara R, Liu Z et al. The effects of anticholinergic drugs on cognitive impairment, mental dysfunction and motor dysfunction in patients with neurological disease. 35th Annual Meeting of the ICS, 28 August-2 September 2005 Montreal, Canada. Conference Proceedings.
42. Wyndaele JJ, Gammie A, Bruschini H, De Wachter S, Fry CH, Jabr RI et al. Bladder compliance what does it represent: Can we measure it, and is it clinically relevant? Neurourol Urodyn 2011; 30, 714-722.